Company intelligence / Profile preview

Abarceo Pharma

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

Abarceo Pharma is a preclinical-stage biotech company developing small molecule therapeutics targeting mitochondrial dysfunction, with a primary focus on restoring beta cell function in type 2 diabetes by modulating the VDAC1 protein. The company has demonstrated preclinical proof of concept in animal models and is exploring additional indications such as cardiovascular disease and Alzheimer’s disease.

Therapeutic areas: EndocrinologyCardiovascularNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Abarceo Pharma AD Program

Preclinical

Partnerships

Spin-out from Lund University Diabetes Center; academic collaboration implied but no major pharma partnerships disclosed yet

Beyond the preview

Go deeper on Abarceo Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abarceo Pharma.

Explore the full profile